[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457068":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":41,"locations":49,"responsibleParty":119,"collaborators":36,"id":121,"slug":36,"hasResults":122,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":36,"eligibilityCriteria":126,"healthyVolunteers":122,"sex":127,"minAge":128,"maxAge":36,"enrollmentInfo":129,"targetDuration":36,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":64,"whyStopped":36,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: ALN-APP","EXPERIMENTAL","Participants will be administered a single dose of ALN-APP.",[13],"Drug: ALN-APP",{"label":15,"type":16,"description":17,"interventionNames":18},"Part A: Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Part B:","Participants will be administered multiple doses of ALN-APP.",[13],[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","ALN-APP","ALN-APP will be administered intrathecally (IT)",[9,21],[31],"mivelsiran",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Placebo","Placebo will be administered IT",[15],null,[38],{"name":39,"affiliation":5,"role":40},"Medical Director","STUDY_DIRECTOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":36,"email":46},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":43,"role":44,"phone":48,"phoneExt":36,"email":46},"1-877-256-9526",[50,63,73,82,90,99,107,111],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":36},"Clinical Trial Site","COMPLETED","La Jolla","California","92037","United States",{"type":58,"coordinates":59},"Point",[60,61],-117.2742,32.84727,{"lat":61,"lon":60},{"facility":51,"status":64,"city":65,"state":66,"zip":67,"country":56,"cosmosGeoPoint":68,"geoPoint":72,"contacts":36},"RECRUITING","Indianapolis","Indiana","46202",{"type":58,"coordinates":69},[70,71],-86.15804,39.76838,{"lat":71,"lon":70},{"facility":51,"status":64,"city":74,"state":36,"zip":75,"country":76,"cosmosGeoPoint":77,"geoPoint":81,"contacts":36},"Montreal","H3A 2B4","Canada",{"type":58,"coordinates":78},[79,80],-73.58781,45.50884,{"lat":80,"lon":79},{"facility":51,"status":64,"city":83,"state":36,"zip":84,"country":76,"cosmosGeoPoint":85,"geoPoint":89,"contacts":36},"Toronto","M3B 2S7",{"type":58,"coordinates":86},[87,88],-79.39864,43.70643,{"lat":88,"lon":87},{"facility":51,"status":64,"city":91,"state":36,"zip":92,"country":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":36},"Amsterdam","1081 BT","Netherlands",{"type":58,"coordinates":95},[96,97],4.88969,52.37403,{"lat":97,"lon":96},{"facility":51,"status":52,"city":100,"state":36,"zip":101,"country":93,"cosmosGeoPoint":102,"geoPoint":106,"contacts":36},"Groningen","9713 GG",{"type":58,"coordinates":103},[104,105],6.56667,53.21917,{"lat":105,"lon":104},{"facility":51,"status":64,"city":108,"state":36,"zip":109,"country":110,"cosmosGeoPoint":36,"geoPoint":36,"contacts":36},"Huntley Street","WC1E 6AG","United Kingdom",{"facility":51,"status":64,"city":112,"state":36,"zip":113,"country":110,"cosmosGeoPoint":114,"geoPoint":118,"contacts":36},"Sheffield","S10 2JF",{"type":58,"coordinates":115},[116,117],-1.4659,53.38297,{"lat":117,"lon":116},{"type":120,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100457068",false,"NCT05231785","A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD","A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD)","Inclusion Criteria:\n\n* Has mild cognitive impairment or mild dementia due to EOAD\n* Has Clinical Dementia Rating (CDR) global score 0.5 or 1.0 and Mini Mental State Examination (MMSE) \\>20\n\nExclusion Criteria:\n\n* Has Non-Alzheimer's disease dementia\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2×upper limit of normal (ULN)\n* Has estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73m\\^2 at Screening\n* Has recently received an investigational agent\n* Has recent treatment with amyloid-targeting antibody\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply","ALL","18 Years",{"count":130,"type":131},60,"ESTIMATED","INTERVENTIONAL",[134],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.",[137],"Early-Onset Alzheimer Disease",[139],"EOAD","2026-06-10",{"date":142,"type":143},"2026-06-12","ACTUAL",{"date":145,"type":143},"2022-02-04",{"date":147,"type":131},"2029-04-20",{"name":5,"class":6},8]